Influenza treatment

Cocrystal Pharma Engages CRO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344

Retrieved on: 
Monday, August 8, 2022
Influenza treatment, Risk, Medicines and Healthcare products Regulatory Agency, United Kingdom, GLOBE, Nobel Prize, Private Securities Litigation Reform Act, CRO, SEC, Cocrystal, Federal Reserve, Annual report, Patient, COVID-19, Company, Influenza, Program, COCP, Vaccine, Safety, CAGR, Nasdaq, Severe acute respiratory syndrome coronavirus 2, AIM, Norovirus, Pharmaceutical industry

The fact that influenza virus is constantly mutating against existing influenza antiviral drugs elevates an urgent need for effective antiviral therapeutics.

Key Points: 
  • The fact that influenza virus is constantly mutating against existing influenza antiviral drugs elevates an urgent need for effective antiviral therapeutics.
  • Open Orphan is a world leader in conducting human challenge clinical trials with antiviral drug candidates, making it an ideal partner for conducting our Phase 2a trial.
  • The single-center, double-blind, placebo-controlled Phase 2a human challenge trial is designed to evaluate safety, viral and clinical measures of orally administered CC-42344 to subjects challenged with influenza A.
  • Enrollment in the multiple-ascending dose portion of the Phase 1 trial is ongoing, with full trial results expected in 2022.

Genentech Announces FDA Approval of Xofluza for the Prevention of Influenza Following Contact With an Infected Person

Retrieved on: 
Monday, November 23, 2020
Infectious diseases, Biotechnology, Pharmaceutical, Health, Chemical compounds, Organic compounds, Medical specialties, Animal virology, Prodrugs, Influenza, Baloxavir marboxil, Influenza treatment, Influenza vaccine, BLOCKSTONE, Xofluza® (baloxavir marboxil), Genentech in Influenza, Genentech

BLOCKSTONE evaluated Xofluza compared with placebo as a preventive treatment for household members (adults and children) who were living with someone with influenza.

Key Points: 
  • BLOCKSTONE evaluated Xofluza compared with placebo as a preventive treatment for household members (adults and children) who were living with someone with influenza.
  • Xofluza showed a statistically significant prophylactic effect on influenza after a single oral dose in people exposed to an infected household contact.
  • Xofluza is also approved for post-exposure prophylaxis of influenza in people 12 years of age and older following contact with an individual who has influenza.
  • Prevent the flu in people 12 years of age and older following contact with a person who has the flu.

Cidara Therapeutics Announces New Clinical and Preclinical Data for Rezafungin and Influenza AVCs from the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Retrieved on: 
Tuesday, May 5, 2020
RTT, Infectious diseases, Medicine, Neuraminidase inhibitors, Drugs, Antivirals, Genentech, Influenza treatment, Oseltamivir, Influenza A virus subtype H1N1, Influenza

"Our data accepted for ECCMID 2020 highlight critical clinical and preclinical efficacy differentiation for our programs.

Key Points: 
  • "Our data accepted for ECCMID 2020 highlight critical clinical and preclinical efficacy differentiation for our programs.
  • Moreover, the time to negative blood culture in the rezafungin-treated patients was statistically faster than that in caspofungin treated patients.
  • These findings show early efficacy of rezafungin and support front-loaded plasma exposure as a pharmacometric determinant of efficacy.
  • Preclinical in vitro data show lower resistance potential of CD377 compared to approved influenza treatments, baloxavir and oseltamivir, against a pandemic strain of influenza.

FDA Accepts Genentech’s New Drug Application for Xofluza for the Treatment of Influenza in Children

Retrieved on: 
Friday, March 27, 2020
FDA, Health, Infectious diseases, Clinical trials, Pharmaceutical, Biotechnology, Infectious diseases, RTT, Organic compounds, Chemical compounds, Antivirals, Genentech, Influenza, Baloxavir marboxil, Zanamivir, Influenza treatment, miniSTONE-2, BLOCKSTONE, Xofluza® (baloxavir marboxil), Genentech in Influenza, Genentech

Todays milestone brings us closer to providing single-dose Xofluza to children with influenza, said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development.

Key Points: 
  • Todays milestone brings us closer to providing single-dose Xofluza to children with influenza, said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development.
  • We also look forward to working with the FDA to incorporate Xofluza as a preventive treatment following exposure to influenza.
  • Xofluza tablets are currently approved in many countries around the world for the treatment of influenza types A and B.
  • BLOCKSTONE evaluated Xofluza compared with placebo as a preventive treatment for household members (adults and children) who were living with someone with influenza.

Genentech Announces FDA Approval of Xofluza (Baloxavir Marboxil) for People at High Risk of Developing Influenza-Related Complications

Retrieved on: 
Thursday, October 17, 2019
Biotechnology, FDA, Health, Pharmaceutical, Clinical trials, Organic compounds, Infectious diseases, Chemical compounds, RTT, Antivirals, Genentech, Baloxavir marboxil, Influenza, Influenza treatment, Oseltamivir, CAPSTONE-2, Xofluza, Genentech in Influenza, Genentech

The flu has the potential to cause a variety of complications, ranging from sinus or ear infections to more serious complications such as pneumonia.

Key Points: 
  • The flu has the potential to cause a variety of complications, ranging from sinus or ear infections to more serious complications such as pneumonia.
  • Xofluza significantly reduced the time to improvement of flu symptoms compared to placebo, including in people infected with the flu type B virus.
  • Xofluza is currently approved in several countries for the treatment of flu types A and B.
  • Do not take XOFLUZA if you are allergic to baloxavir marboxil or any of the ingredients in XOFLUZA.

With Sick Season Approaching, Theraflu® Expands #1 Hot Liquid Cold and Flu Treatment Portfolio* With Targeted Cough Relief Treatment

Retrieved on: 
Tuesday, October 15, 2019
Songs, Cold medicine, Common cold, Influenza treatment, Cold, Cough

New Theraflu Cough Relief contains a 2-in-1 formulation for effective relief of dry and wet cough in a warm soothing liquid.

Key Points: 
  • New Theraflu Cough Relief contains a 2-in-1 formulation for effective relief of dry and wet cough in a warm soothing liquid.
  • Theraflu Cough Relief is the newest addition to the hot liquid cold and flu treatment product line.
  • With consumers increasingly integrating sensorial experiences into their wellness routine, Theraflu offers a variety of hot liquid powder products as a way for cold and flu sufferers to treat their symptoms.
  • "We want to make it easier for consumers this cold and flu season by delivering relief when they need it most.

Cocrystal Pharma Announces Abstract Accepted for Oral Presentation at the ISIRV: Options X for the Control of Influenza Conference

Retrieved on: 
Wednesday, August 21, 2019
Infectious diseases, Viruses, Medical specialties, Animal virology, Antiviral drug, Biocides, Influenza, Flu season, Influenza treatment, Influenza A virus subtype H5N1

The details for the Companys oral presentation are as follows:

Key Points: 
  • The details for the Companys oral presentation are as follows:
    The ISIRV is an independent and international scientific professional society promoting the prevention, detection, treatment, and control of influenza and other respiratory virus diseases.
  • Options X, the 10th edition of the Options for the Control of Influenza conference, is ISIRV's premier event and remains the largest international conference exclusively dedicated to influenza prevention, control and treatment, including seasonal flu and pandemic preparedness.
  • Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses.
  • Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs.

Genentech Announces Positive Results for First Global Phase III Study Investigating One-dose XOFLUZA (Baloxavir Marboxil) in Children With the Flu

Retrieved on: 
Wednesday, July 3, 2019
Children, FDA, Clinical trials, Biotechnology, Pharmaceutical, Consumer, Health, RTT, Infectious diseases, Chemical compounds, Medicine, Antivirals, Genentech, Oseltamivir, Prodrugs, Influenza, Baloxavir marboxil, Flu pandemic, Influenza treatment, MINISTONE-2 (NCT03629184), XOFLUZA™ (baloxavir marboxil), Genentech in influenza, Genentech

The study also showed that XOFLUZA is comparable to oseltamivir a proven effective treatment for children with the flu at reducing the duration of flu symptoms, including fever.

Key Points: 
  • The study also showed that XOFLUZA is comparable to oseltamivir a proven effective treatment for children with the flu at reducing the duration of flu symptoms, including fever.
  • The study assessed XOFLUZA versus an active comparator (oseltamivir) in children aged between one and less than 12 years old with the flu.
  • Children need new medicines for the flu because they are at higher risk of developing the flu and more likely to have complications such as breathing problems and pneumonia.
  • The safety and efficacy of XOFLUZA in children with the flu under the age of one is also being studied in the global Phase III MINISTONE-1 study (NCT03653364).

Influenza Clinical Trial Pipeline Highlights, 2019-2024 - Phase 3, 2, & 1 Clinical Trials, Preclinical Research, and Discovery Stage - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 12, 2019
Professional services, Consulting, Health, Medicine, Clinical research, Design of experiments, Drug discovery, RTT, Clinical trial, Pharmaceutical industry, Influenza, Influenza pandemic, Influenza treatment

The "Global Influenza Clinical Trial Pipeline Highlights - 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Influenza Clinical Trial Pipeline Highlights - 2019" report has been added to ResearchAndMarkets.com's offering.
  • Influenza Pipeline Highlights - 2019, provides most up-to-date information on key pipeline products in the global Influenza market.
  • It covers emerging therapies for Influenza in active clinical development stages including early and late stage clinical trials.
  • The report provides Influenza pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Influenza Clinical Trial Pipeline Highlights 2019 - Track Competition, Identifying Partners, & Evaluate Opportunities

Retrieved on: 
Wednesday, June 5, 2019
Health, Medicine, Drug discovery, Clinical research, Design of experiments, RTT, Clinical trial, Pharmaceutical industry, Influenza, Influenza pandemic, Influenza treatment

DUBLIN, June 5, 2019 /PRNewswire/ -- The "Global Influenza Clinical Trial Pipeline Highlights - 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, June 5, 2019 /PRNewswire/ -- The "Global Influenza Clinical Trial Pipeline Highlights - 2019" report has been added to ResearchAndMarkets.com's offering.
  • Influenza Pipeline Highlights - 2019, provides most up-to-date information on key pipeline products in the global Influenza market.
  • It covers emerging therapies for Influenza in active clinical development stages including early and late stage clinical trials.
  • The report provides Influenza pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.